Literature DB >> 20642541

A manifesto for clinical pharmacology from principles to practice.

Jeffrey K Aronson1.   

Abstract

1. This is a manifesto for UK clinical pharmacology. 2. A clinical pharmacologist is a medically qualified practitioner who teaches, does research, frames policy, and gives information and advice about the actions and proper uses of medicines in humans and implements that knowledge in clinical practice. Those without medical qualifications who practise some aspect of clinical pharmacology could be described as, say, 'applied pharmacologists'. 3. Clinical pharmacology is operationally defined as a translational discipline in terms of the basic tools of human pharmacology (e.g. receptor pharmacology) and applied pharmacology (e.g. pharmacokinetics) and how they are used in drug discovery and development and in solving practical therapeutic problems in individuals and populations. 4. Clinical pharmacologists are employed by universities, health-care services, private organizations (such as drug companies), and regulatory agencies. They are mentors and teachers, teaching laboratory science, clinical science, and all aspects of practical drug therapy as underpinned by the science of pharmacology; they write and edit didactic and reference texts; researchers, covering research described by the operational definition; clinicians, practising general medicine, clinical toxicology, other medical specialties, and general practice; policy makers, framing local, national, and international medicines policy, including formularies, licensing of medicines and prescribing policies. 5. The future of clinical pharmacology depends on the expansion and maintenance of a central core of practitioners (employed by universities or health-care services), training clinical pharmacologists to practise in universities, health-care services, private organizations, and regulatory agencies, and training other clinicians in the principles and practice of clinical pharmacology.

Entities:  

Mesh:

Year:  2010        PMID: 20642541      PMCID: PMC2909801          DOI: 10.1111/j.1365-2125.2010.03699.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

Review 2.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Balanced prescribing.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

4.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

5.  Mentoring: what's in a name?

Authors:  Dario Sambunjak; Ana Marusić
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

Review 6.  Integrating genomics, proteomics and bioinformatics in translational studies of molecular medicine.

Authors:  Jerzy Ostrowski; Lucjan S Wyrwicz
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

7.  Medication errors: definitions and classification.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2009-06       Impact factor: 4.335

8.  Rational prescribing in primary care--a new role for clinical pharmacology?

Authors:  T Walley
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

9.  Scientific basis for the support of biomedical science.

Authors:  J H Comroe; R D Dripps
Journal:  Science       Date:  1976-04-09       Impact factor: 47.728

Review 10.  Mentoring in academic medicine: a systematic review.

Authors:  Dario Sambunjak; Sharon E Straus; Ana Marusić
Journal:  JAMA       Date:  2006-09-06       Impact factor: 56.272

View more
  19 in total

Review 1.  From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?

Authors:  A Richard Green; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Finding a VOICE for UK clinical pharmacology.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

3.  Clinical pharmacology: a declaration of intent.

Authors:  A Somogyi; Y K Loke; A Ferro; L D Lewis; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

4.  A response to: 'A manifesto for clinical pharmacology from principles to practice' by Jeff Aronson.

Authors:  Clive Page
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  Towards a single VOICE for European clinical pharmacology: proposals for future developments.

Authors:  Jeffrey K Aronson; Giampaolo Velo
Journal:  Eur J Clin Pharmacol       Date:  2013-07-03       Impact factor: 2.953

6.  What's in a name?

Authors:  Geoffrey T Tucker; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

7.  An alternative view of the role of clinical pharmacology.

Authors:  J Desmond Fitzgerald
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

8.  What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

9.  The specialty clinical pharmacology needs to be examined separately to guarantee a sufficient level of knowledge in medical students.

Authors:  Susanna M Wallerstedt; Mattias Wallerstedt; Sven Wallerstedt
Journal:  Eur J Clin Pharmacol       Date:  2012-12-19       Impact factor: 2.953

10.  Clinical Pharmacology Knowledge, Opportunities and Working Strengths (CPKNOWS): a competency model for pursuit of excellence in clinical pharmacology.

Authors:  Keith A Nieforth; Hisham Y Abdallah; Patrick Smith; Michael Derks; Bruno Boutouyrie; Nenad Sarapa; Richard W Peck
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.